Aprea Therapeutics (NASDAQ:APRE – Get Free Report) and Ventyx Biosciences (NASDAQ:VTYX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.
Valuation & Earnings
This table compares Aprea Therapeutics and Ventyx Biosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aprea Therapeutics | $1.50 million | 5.60 | -$12.96 million | ($2.32) | -0.62 |
| Ventyx Biosciences | N/A | N/A | -$135.12 million | ($1.68) | -1.37 |
Risk & Volatility
Aprea Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings for Aprea Therapeutics and Ventyx Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aprea Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Ventyx Biosciences | 0 | 1 | 1 | 0 | 2.50 |
Aprea Therapeutics currently has a consensus price target of $15.50, suggesting a potential upside of 976.39%. Ventyx Biosciences has a consensus price target of $7.50, suggesting a potential upside of 226.09%. Given Aprea Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Aprea Therapeutics is more favorable than Ventyx Biosciences.
Institutional and Insider Ownership
34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 97.9% of Ventyx Biosciences shares are held by institutional investors. 13.6% of Aprea Therapeutics shares are held by company insiders. Comparatively, 14.5% of Ventyx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Aprea Therapeutics and Ventyx Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aprea Therapeutics | -1,645.01% | -78.90% | -62.67% |
| Ventyx Biosciences | N/A | -48.89% | -44.87% |
Summary
Aprea Therapeutics beats Ventyx Biosciences on 7 of the 13 factors compared between the two stocks.
About Aprea Therapeutics
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
About Ventyx Biosciences
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
